The Technical Analyst
Select Language :
Prothena Corporation PLC [PRTA]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology

Prothena Corporation PLC Price, Forecast, Insider, Ratings, Fundamentals & Signals

Current Signal: BUY (auto-tracking)

Prothena Corporation PLC is listed at the  Exchange

-1.55% $24.77

America/New_York / 28 mar 2024 @ 16:00


Prothena Corporation PLC: Main Fundamentals PE comparison

FUNDAMENTALS
MarketCap: 1 330.66 mill
EPS: -2.76
P/E: -8.97
Earnings Date: Apr 28, 2024
SharesOutstanding: 53.72 mill
Avg Daily Volume: 0.823 mill
RATING 2024-03-28
B-
Sell
RATINGS
Rating CashFlow: Strong Sell
Return On Equity: Sell
Return On Asset: Neutral
DE: Sell
P/E: Strong Sell
Price To Book: Strong Buy
QUARTER GROWTHS
3/224/221/232/233/234/23
Revenue
Gr.Profit
Ebit
Asset
Debt
PE RATIO: COMPANY / SECTOR
0.00x
Company: PE -8.97 | sector: PE -3.05
PE RATIO: COMPANY / INDUSTRY
-1.53x
Company: PE -8.97 | industry: PE 5.88
DISCOUNTED CASH FLOW VALUE
N/A
N/A
Expected Trading Range (DAY)

$ 23.11 - 26.43

( +/- 6.71%)
ATR Model: 14 days

Insider Trading

Date Person Action Amount type
2024-03-01 Ford David A Buy 85 000 Stock Option (Right to Buy)
2024-03-01 Ford David A Buy 0
2024-02-27 Zago Wagner M. Buy 85 000 Stock Option (Right to Buy)
2024-02-27 Walker Karin L Buy 54 000 Stock Option (Right to Buy)
2024-02-27 Smith Brandon S. Buy 85 000 Stock Option (Right to Buy)
INSIDER POWER
77.45
Last 98 transactions
Buy: 1 184 000 | Sell: 192 000

Forecast: 16:00 - $24.77

Live Trading Signals (every 1 min)

Forecast 1: 16:00 - $24.77
Forecast 2: 16:00 - $24.77
Forecast 3: 16:00 - $24.77
SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD
Volume Signals
Price $24.77 (-1.55% )
Volume 0.773 mill
Avg. Vol. 0.823 mill
% of Avg. Vol 93.92 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for Prothena Corporation PLC

Last 12 Months

Last 12 months chart data with high, low, open and close for Prothena Corporation PLC

RSI

Intraday RSI14 chart for Prothena Corporation PLC

Last 10 Buy & Sell Signals For PRTA

0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%

Avg return buy: 0.00 % | Avg return sell: 0.00 %

$1 invested is now $1.00 or 0.00% since Coming Soon

Date Signal @ Closed %
Feb 8 - 15:33sell$27.29N/AActive
Profile picture for
            Prothena Corporation PLC

PRTA

Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.

Last 10 Buy Signals

Date Signal @
WBTUSDMar 28 - 18:438.37
TRXUSDMar 28 - 18:39$0.120
XMRUSDMar 28 - 18:34$135.06
IONUSDMar 28 - 18:23454.85
APE18876USDMar 28 - 18:212.02
DAOUSDMar 28 - 18:19$1.823
TONUSDMar 28 - 18:134.88
STXUSDMar 28 - 18:19$3.43
SFRXETHUSDMar 28 - 18:153 791.50
BTC.BUSDMar 28 - 18:1470 390

Latest Press Releases

Latest News

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.